Home > About us > Our Commitments > Philanthropic commitment

Engagement Philanthropic

talenco is committed to the research in neuroscience.

Supporting research in Neurosciences

Because innovation is nothing if it does not serve men, talenco has focused its philanthropic commitment since 2015 on research against brain diseases through its involvement in bretagne atlantique ambition (BAA), a funding fund dedicated to research and innovation in the West.

Our commitment Philanthropic for research in neuroscience

Created by emblematic Western business leaders such as Roland Beaumanoir (Groupe Beaumanoir) and Christian Roulleau (Groupe Samsic), the fund bretagne atlantique ambition It brings together companies, sponsors and researchers around a common cause: supporting medical research in the field of neuroscience to combat pathologies such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis or epilepsy.

Since 2015, talenco has been actively involved within BAA fund the hiring of young researchers and support these talents in cutting-edge initiatives. 10% of talenco’s results are paid each year to BAA, and Jean-Baptiste Gouin, co-founder and CEO of talenco, has also been the chairman of the fund since 2020.

Thanks to its actions and the donations collected since the creation of the fund in 2014, bretagne atlantique ambition was able, through the’INCR, finance more 70 research projects on brain diseases and collected more than 3.5 million euros corresponding to 1,056 months of research (funding for researchers).

We are all affected, directly or indirectly, by brain diseases. Alzheimer’s, Parkinson’s, multiple sclerosis… These are terrible trials. Our goal, with bretagne atlantique ambition, is to fund research to understand and combat these diseases and to be able to retain the talents of the region in the field of research.

Because one day, thanks to science, we will most likely be able to eliminate these debilitating pathologies.

Jean Baptiste GOUIN | CEO of talenco and president of BAA

Projects Concrete thanks to BAA and the INCR

The Institute of Clinical Neurosciences of Rennes (INCR) is a pillar of medical research in neurosciences in Brittany. It brings together a talented team of researchers (from Inserm and Inria) and clinicians working on serious diseases such as Parkinson’s disease, Alzheimer’s disease, epilepsy, stroke and brain cancer.

Thanks to donations, INCR finances concrete projects aimed at improving the treatments and the quality of life of patients. The BAA fund contributes to the funding of this Rennes institute, a key player in the fight against cancer. to maintain French excellence in medical research.

Since 2014, the action of bretagne atlantique ambition has also enabled:

publish nearly 1,500 publications in the most prestigious international scientific journals,
contribute to a European price for scientific excellence,
to support 2 talents who have created 2 startups,
Strengthen the recognition of neurology in the West with projects funded in collaboration with the CHU of Rennes, Brest, Nantes and Angers.

There are still many projects and promises for the future, and more than ever, talenco is committed to supporting them:

the ability to predict the development of disability in multiple sclerosis,
find an effective treatment for brain cancer,
improve the effectiveness of deep brain stimulation in Parkinson’s disease, etc.

Some examples of Projects funded by BAA

ACTIDIFF

Towards a better understanding of apathy and its links with depression and dementia in the elderly.

CREAPARK

Parkinson's disease and creativity: exploring brain networks to understand the impacts.

DETECT VIB FOG

exploring muscle vibrations to understand and treat episodes of FOG (freezing of gait or kinetic inhibition).

ECOFEC

evolution of cognitive functions under the effect of epileptic activity in children.

IRE DUAL

Towards personalized medicine for glioblastoma through tumor stratification.

INCA

Individual analysis of attention during a neurofeedback session for clinical applications.

M4LPB

Multimodal MRI and automatic learning for biomarkers of Parkinson's disease.

PSY NORM

revealing the heterogeneity of psychiatric disorders through normative modeling.

10 years ago, I never imagined that this philanthropic commitment would allow me to meet so many talented people, doctors, researchers, entrepreneurs… This commitment is thus a tremendous enrichment in everyday life.

Furthermore, the constant contact with internationally renowned neuroscientists allows talenco to stay at the forefront of the latest advances in neuroscience and to offer its clients the most impactful teaching methods derived from research.

Jean Baptiste GOUIN CEO of talenco and President of BAA